## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.88 indicates fundamental undervaluation. Caution: momentum weakening (-2.7% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($309.94)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Elevance Health, Inc. (ELV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation**
- Source: WHO13.com | 20251130T110000 | Neutral | Relevance: 99%
- Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential corporate wrongdoing at Elevance Health, Inc. (NYSE:ELV). The firm is encouraging investors who purchased Elevance securities prior to April 18, 2024, and still hold them, to contact them for more information and to assist in the investigation. The investigation focuses on whether Elevance and its officers/directors engaged in misconduct.

**2. Elevance Health, Inc. (ELV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation**
- Source: CBS 42 | 20251130T110000 | Neutral | Relevance: 98%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Elevance Health, Inc. (NYSE:ELV) regarding potential corporate wrongdoing. The firm is encouraging stockholders who purchased Elevance securities before April 18, 2024, and still hold them, to come forward and assist in their investigation. The investigation aims to determine if Elevance and its officers/directors engaged in illegal activities.

**3. Scotia Capital Inc. Has $8.87 Million Holdings in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251201T042232 | Bullish | Relevance: 97%
-  Scotia Capital Inc. increased its stake in Elevance Health, Inc. (NYSE:ELV) by 5.6% to 22,812 shares, now valued at approximately $8.87 million. Elevance Health exceeded Q3 expectations with an EPS of $6.03 and revenues of $50.09 billion, and declared a quarterly dividend of $1.71 per share. Despite a consensus "Hold" rating from analysts with an average price target of $398.44, the stock's performance shows a 1-year low of $273.71 and a 1-year high of $458.75.

**4. Humana appeals Medicare Advantage star ratings loss to 5th Circuit**
- Source: Healthcare Dive | 20251201T162133 | Neutral | Relevance: 65%
- Humana is appealing its Medicare Advantage star ratings loss to the 5th Circuit Court of Appeals, continuing its legal battle against the government's recalculation of scores that could impact its bonus payments by an estimated $1 billion or more in 2026. The insurer maintains that the Centers for Medicare & Medicaid Services (CMS) acted arbitrarily in downgrading its quality scores based on unsuccessful customer service calls. This move follows multiple setbacks in lower courts and comes amidst proposed changes by the Trump administration to Medicare Advantage star ratings measures, including one focused on call center performance.

**5. Brown & Brown Employer Health and Benefits Strategy Survey | 2026 Edition**
- Source: Brown & Brown | 20251201T190628 | Neutral | Relevance: 60%
- Brown & Brown's second annual Employer Health and Benefits Strategy Survey for 2026 highlights rising costs, evolving workforce needs, and a focus on innovation and sustainability as key shapers of the benefits landscape. The survey, which included 1,241 employers, found a shift in strategic priorities, with cost control now topping the list for both employees and employers. Attracting and retaining a healthy and engaged workforce, previously the top priority, moved to third place.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | TD Cowen | $400 | $380 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Long-term trend broken: trading 8.4% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.88 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +5%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $76.8B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.88 |
| Forward P/E | 12.1 |
| Current P/E | 11.0 |
| YoY Growth | -9.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.6% to 1.0% (-2.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.0pp (needs >4.0% for momentum thesis). MRS_5 (-2.0%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.92x), long-term trend not supportive. MACD histogram positive (2.04), confirming momentum. RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.96% (CS: 62) | Neutral |
| RSI_14 | 51.0 | Neutral |
| MACD Histogram | 2.04 | Bullish |
| vs SMA20 | 1.021x | Above |
| vs SMA50 | 0.990x | Below |
| vs SMA200 | 0.916x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $329.68
- **Stop Loss:** $309.94 (6.0% risk)
- **Target:** $369.16 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 37
- **Position Value:** $12,198.16
- **Portfolio %:** 12.20%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*